234 related articles for article (PubMed ID: 31515067)
1. High-dose-rate vs. low-dose-rate interstitial brachytherapy boost for anal canal cancers.
Varela Cagetti L; Zemmour C; Salem N; Minsat M; Ferrè M; Mailleux H; Giovaninni M; Lelong B; De Chaisemartin C; Ries P; Poizat F; Tallet A; Moureau-Zabotto L
Brachytherapy; 2019; 18(6):814-822. PubMed ID: 31515067
[TBL] [Abstract][Full Text] [Related]
2. Low-dose-rate interstitial brachytherapy boost for the treatment of anal canal cancers.
Cordoba A; Escande A; Leroy T; Mirabel X; Coche-Dequéant B; Lartigau E
Brachytherapy; 2017; 16(1):230-235. PubMed ID: 27600606
[TBL] [Abstract][Full Text] [Related]
3. The impact of brachytherapy boost for anal canal cancers in the era of de-escalation treatments.
Varela Cagetti L; Moureau-Zabotto L; Zemmour C; Ferré M; Giovaninni M; Poizat F; Lelong B; De Chaisemartin C; Mitry E; Tyran M; Zioueche-Mottet A; Salem N; Tallet A
Brachytherapy; 2023; 22(4):531-541. PubMed ID: 37150739
[TBL] [Abstract][Full Text] [Related]
4. High-dose-rate versus low-dose-rate brachytherapy in the treatment of cervical cancer: analysis of tumor recurrence--the University of Wisconsin experience.
Petereit DG; Sarkaria JN; Potter DM; Schink JC
Int J Radiat Oncol Biol Phys; 1999 Dec; 45(5):1267-74. PubMed ID: 10613322
[TBL] [Abstract][Full Text] [Related]
5. Transition from LDR to HDR brachytherapy for cervical cancer: Evaluation of tumor control, survival, and toxicity.
Romano KD; Pugh KJ; Trifiletti DM; Libby B; Showalter TN
Brachytherapy; 2017; 16(2):378-386. PubMed ID: 28139420
[TBL] [Abstract][Full Text] [Related]
6. Concurrent chemoradiation for cervical cancer: Comparison of LDR and HDR brachytherapy.
Lin AJ; Samson P; Zoberi J; Garcia-Ramirez J; Williamson JF; Markovina S; Schwarz J; Grigsby PW
Brachytherapy; 2019; 18(3):353-360. PubMed ID: 30971370
[TBL] [Abstract][Full Text] [Related]
7. Low-dose-rate vs. high-dose-rate intracavitary brachytherapy for carcinoma of the cervix: The University of Alabama at Birmingham (UAB) experience.
Falkenberg E; Kim RY; Meleth S; De Los Santos J; Spencer S
Brachytherapy; 2006; 5(1):49-55. PubMed ID: 16563997
[TBL] [Abstract][Full Text] [Related]
8. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
[TBL] [Abstract][Full Text] [Related]
9. Comparison of low and high dose rate brachytherapy in the treatment of uterine cervix cancer. Retrospective analysis of two sequential series.
Ferrigno R; Nishimoto IN; Novaes PE; Pellizzon AC; Maia MA; Fogarolli RC; Salvajoli JV
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):1108-16. PubMed ID: 15990016
[TBL] [Abstract][Full Text] [Related]
10. Interstitial high-dose rate brachytherapy as boost for anal canal cancer.
Falk AT; Claren A; Benezery K; François E; Gautier M; Gerard JP; Hannoun-Levi JM
Radiat Oncol; 2014 Nov; 9():240. PubMed ID: 25377886
[TBL] [Abstract][Full Text] [Related]
11. Brachytherapy for Buccal Cancer: From Conventional Low Dose Rate (LDR) or Mold Technique to High Dose Rate Interstitial Brachytherapy (HDR-ISBT).
Kotsuma T; Yamazaki H; Masui K; Yoshida K; Shimizutani K; Akiyama H; Murakami S; Isohashi F; Yoshioka Y; Ogawa K; Tanaka E
Anticancer Res; 2017 Dec; 37(12):6887-6892. PubMed ID: 29187469
[TBL] [Abstract][Full Text] [Related]
12. From low-dose-rate to high-dose-rate brachytherapy in lip carcinoma: Equivalent results but fewer complications.
Guinot JL; Arribas L; Tortajada MI; Crispín V; Carrascosa M; Santos M; Mut A; Vendrell JB; Pesudo C; Chust ML
Brachytherapy; 2013; 12(6):528-34. PubMed ID: 23850275
[TBL] [Abstract][Full Text] [Related]
13. High-dose-rate brachytherapy monotherapy versus low-dose-rate brachytherapy with or without external beam radiotherapy for clinically localized prostate cancer.
Yamazaki H; Masui K; Suzuki G; Nakamura S; Yamada K; Okihara K; Shiraishi T; Yoshida K; Kotsuma T; Tanaka E; Otani K; Yoshioka Y; Ogawa K
Radiother Oncol; 2019 Mar; 132():162-170. PubMed ID: 30416045
[TBL] [Abstract][Full Text] [Related]
14. High dose rate versus low dose rate intracavity brachytherapy for locally advanced uterine cervix cancer.
Wang X; Liu R; Ma B; Yang K; Tian J; Jiang L; Bai ZG; Hao XY; Wang J; Li J; Sun SL; Yin H
Cochrane Database Syst Rev; 2010 Jul; (7):CD007563. PubMed ID: 20614461
[TBL] [Abstract][Full Text] [Related]
15. Results of low- and high-dose-rate interstitial brachytherapy for T3 mobile tongue cancer.
Kakimoto N; Inoue T; Inoue T; Murakami S; Furukawa S; Yoshida K; Yoshioka Y; Yamazaki H; Tanaka E; Shimizutani K
Radiother Oncol; 2003 Aug; 68(2):123-8. PubMed ID: 12972306
[TBL] [Abstract][Full Text] [Related]
16. A comparative analysis of overall survival between high-dose-rate and low-dose-rate brachytherapy boosts for unfavorable-risk prostate cancer.
King MT; Yang DD; Muralidhar V; Mahal B; Butler S; Devlin PM; Lee LJ; Mouw KW; Martin NM; D'Amico AV; Nguyen PL; Orio PF
Brachytherapy; 2019; 18(2):186-191. PubMed ID: 30638912
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcome after treatment with a brachytherapy boost versus external beam boost for anal carcinoma.
Oehler-Jänne C; Seifert B; Lütolf UM; Studer G; Glanzmann C; Ciernik IF
Brachytherapy; 2007; 6(3):218-26. PubMed ID: 17681244
[TBL] [Abstract][Full Text] [Related]
18. After low and high dose-rate interstitial brachytherapy followed by IMRT radiotherapy for intermediate and high risk prostate cancer.
Nakamura S; Murakami N; Inaba K; Wakita A; Kobayashi K; Takahashi K; Okamoto H; Umezawa R; Morota M; Sumi M; Igaki H; Ito Y; Itami J
BMC Cancer; 2016 May; 16():296. PubMed ID: 27142069
[TBL] [Abstract][Full Text] [Related]
19. High-dose versus low-dose rate brachytherapy in definitive radiotherapy of cervical cancer.
Kucera H; Pötter R; Knocke TH; Baldass M; Kucera E
Wien Klin Wochenschr; 2001 Jan; 113(1-2):58-62. PubMed ID: 11233470
[TBL] [Abstract][Full Text] [Related]
20. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds.
Grills IS; Martinez AA; Hollander M; Huang R; Goldman K; Chen PY; Gustafson GS
J Urol; 2004 Mar; 171(3):1098-104. PubMed ID: 14767279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
